Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Evercore ISI lifts CVS Health stock target to $65, keeps Outperform
Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,
Should You Buy CVS Health Stock Before Feb. 12?
CVS Health (NYSE: CVS) is a big name in healthcare, and it has generally been seen as a good way to invest in the industry. In addition to its pharmacy retail operations, the company has a pharmacy benefits management business.
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this drugstore chain and pharmacy benefits manager have returned +27.
13d
UnitedHealth Group CEO says complex US healthcare system needs to change
UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector ...
2h
on MSN
How killing of UnitedHealthcare CEO sowed fear for executives’ safety
After UnitedHealthcare CEO Brian Thompson was shot to death in December, law enforcement records show a burst of police ...
Newsweek
12d
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC
The FTC report showed that from 2017 to 2022, the three PBMs—
UnitedHealth
Group
's Optum,
CVS
Health
's
CVS
Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by ...
Benefits Pro
13d
UnitedHealth's PBM will pass 100% of rebates on to clients: Will more big PBMs follow?
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
13d
on MSN
Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Newsweek on MSN
12d
UnitedHealth CEO Defends Company Amid Price Gouging Accusations
Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's ...
7d
'It's Out of Control': UnitedHealth Group and Peers Charged Americans 1000% More for Drugs
FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback